Clinical Scorecard: Factors Influencing Survival and Comparative Analysis of 183 Patients with Myelofibrosis Treated with Momelotinib, Ruxolitinib, Fedratinib, or BMS-911543 JAK2 Inhibitor

At a Glance

Key Highlights

• Ruxolitinib, fedratinib, and pacritinib are FDA-approved JAK2 inhibitors; momelotinib is pending approval.
• Momelotinib shows comparable spleen response to ruxolitinib but superior anemia improvement and longer treatment duration.
• High discontinuation rates observed (92% at 5 years), mainly due to suboptimal response or progressive disease.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of PMF, post-ET, and post-PV MF should follow conventional criteria.
• Baseline assessment should include transfusion status, spleen size, anemia, and constitutional symptoms per modified IWG-MRT criteria.
• Molecular screening for JAK2, MPL, CALR, ASXL1, SRSF2, IDH1/2, and U2AF1 mutations is recommended.

Management

• Use of JAK2 inhibitors (ruxolitinib, fedratinib, pacritinib) for palliation of splenomegaly and constitutional symptoms.
• Consider momelotinib for patients with anemia due to its anemia response benefit.
• Treatment choice may be influenced by patient age, mutation profile, transfusion dependence, and risk category.

Monitoring & Follow-up

• Regular evaluation of spleen size and symptom response using IWG-MRT criteria.
• Monitor for anemia development, especially in patients treated with ruxolitinib and fedratinib.
• Assess for treatment discontinuation reasons including toxicity, disease progression, and leukemic transformation.

Risks

• Anemia is a common adverse effect with ruxolitinib (42-45%) and fedratinib (43% grade 3/4 anemia).
• High rates of treatment discontinuation due to suboptimal response or progressive disease.
• Potential leukemic transformation and secondary malignancies during therapy.

Patient & Prescribing Data

183 JAKi naïve MF patients enrolled in phase 1/2 clinical trials with median age 65 years, 58% male, 60% primary MF.

Momelotinib patients were older, more transfusion-dependent, and higher risk; momelotinib showed longer treatment duration (21 vs 10 months vs ruxolitinib) and better anemia response; spleen response rates were comparable across JAKi.

Clinical Best Practices

• Select JAK2 inhibitor based on patient-specific factors including anemia status and mutation profile.
• Use modified IWG-MRT criteria for consistent assessment of spleen and anemia response.
• Monitor patients closely for anemia and other toxicities to guide therapy adjustments.
• Consider molecular and risk stratification (DIPSS-plus) to predict response and survival outcomes.
• Plan for management of treatment discontinuation and subsequent therapies due to high discontinuation rates.

References

• FDA-approved JAK2 inhibitors for MF
• COMFORT-1 Study (Ruxolitinib vs Placebo)
• COMFORT-2 Study (Ruxolitinib vs Best Available Therapy)
• SIMPLIFY-1 Study (Momelotinib vs Ruxolitinib)
• JAKARTA-1 Study (Fedratinib in MF)